{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:24:46Z","timestamp":1791915886385,"version":"4.3.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s40257-024-00880-1","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T20:02:52Z","timestamp":1722024172000},"page":"765-778","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Hidradenitis Suppurativa: New Targets and Emerging Treatments"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8420-8594","authenticated-orcid":false,"given":"Julia L.","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6385-0470","authenticated-orcid":false,"given":"Tracey S.","family":"Otto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4738-4385","authenticated-orcid":false,"given":"Martina L.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9405-0479","authenticated-orcid":false,"given":"Alexa B.","family":"Kimball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,26]]},"reference":[{"key":"880_CR1","doi-asserted-by":"crossref","unstructured":"Kimball AB, Kirby J, Ingram JR, Tran T, Pansar I, Ciaravino V, et al. Burden of hidradenitis suppurativa: a systematic literature review of patient reported outcomes. Dermatol Ther. 2024:1-16.","DOI":"10.1007\/s13555-023-01085-w"},{"issue":"2","key":"880_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.12788\/j.sder.2017.017","volume":"36","author":"LK Hoffman","year":"2017","unstructured":"Hoffman LK, Ghias MH, Lowes MA. Pathophysiology of hidradenitis suppurativa. Semin Cutan Med Surg. 2017;36(2):47\u201354.","journal-title":"Semin Cutan Med Surg"},{"key":"880_CR3","unstructured":"Administration UFaD. Resources for You (Biologics). 2019 September 10, 2021 [cited 2024 April 28]; Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/resources-you-biologics"},{"issue":"3","key":"880_CR4","first-page":"156","volume":"99","author":"M Porter","year":"2017","unstructured":"Porter M, Kimball AB. Hidradenitis suppurativa scoring systems: can we choose just one. Cutis. 2017;99(3):156\u20137.","journal-title":"Cutis"},{"key":"880_CR5","unstructured":"Hurley H. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach. Dermatol Surg.729-39."},{"issue":"4","key":"880_CR6","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/j.1365-2133.2009.09198.x","volume":"161","author":"K Sartorius","year":"2009","unstructured":"Sartorius K, Emtestam L, Jemec G, Lapins J. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol. 2009;161(4):831\u20139.","journal-title":"Br J Dermatol"},{"issue":"2","key":"880_CR7","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jaad.2009.06.050","volume":"62","author":"A Grant","year":"2010","unstructured":"Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010;62(2):205\u201317.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"880_CR8","doi-asserted-by":"publisher","first-page":"846","DOI":"10.7326\/0003-4819-157-12-201212180-00004","volume":"157","author":"AB Kimball","year":"2012","unstructured":"Kimball AB, Kerdel F, Adams D, Mrowietz U, Gelfand JM, Gniadecki R, et al. Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med. 2012;157(12):846\u201355.","journal-title":"Ann Intern Med"},{"issue":"6","key":"880_CR9","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/jdv.13216","volume":"30","author":"A Kimball","year":"2016","unstructured":"Kimball A, Sobell J, Zouboulis C, Gu Y, Williams D, Sundaram M, et al. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. J Eur Acad Dermatol Venereol. 2016;30(6):989\u201394.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"880_CR10","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1111\/bjd.15748","volume":"177","author":"C Zouboulis","year":"2017","unstructured":"Zouboulis C, Tzellos T, Kyrgidis A, Jemec G, Bechara F, Giamarellos-Bourboulis E, et al. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol. 2017;177(5):1401\u20139.","journal-title":"Br J Dermatol"},{"issue":"2","key":"880_CR11","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/jdv.18632","volume":"37","author":"T Tzellos","year":"2023","unstructured":"Tzellos T, van Straalen KR, Kyrgidis A, Alavi A, Goldfarb N, Gulliver W, et al. Development and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2023;37(2):395\u2013401.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"880_CR12","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.clindermatol.2023.08.016","volume":"41","author":"ND Koerts","year":"2023","unstructured":"Koerts ND, Bouwman K, Prens LM, Horv\u00e1th B. Assessment tools and phenotype classification for hidradenitis suppurativa. Clin Dermatol. 2023;41(5):601\u201310.","journal-title":"Clin Dermatol"},{"key":"880_CR13","volume-title":"Adalimumab","author":"CR Ellis","year":"2024","unstructured":"Ellis CR, Azmat CE. Adalimumab. Treasure Island, FL: StatPearls Publishing; 2024."},{"issue":"8","key":"880_CR14","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1080\/14656566.2022.2070429","volume":"23","author":"SX Chen","year":"2022","unstructured":"Chen SX, Greif C, Gibson RS, Porter ML, Kimball AB. Advances in biologic and small molecule therapies for hidradenitis suppurativa. Exp Opin Pharmacother. 2022;23(8):959\u201378.","journal-title":"Exp Opin Pharmacother."},{"key":"880_CR15","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s40257-017-0341-6","volume":"19","author":"C Ryan","year":"2018","unstructured":"Ryan C, Sobell JM, Leonardi CL, Lynde CW, Karunaratne M, Valdecantos WC, et al. Safety of adalimumab dosed every week and every other week: focus on patients with hidradenitis suppurativa or psoriasis. Am J Clin Dermatol. 2018;19:437\u201347.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"880_CR16","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1504370","volume":"375","author":"AB Kimball","year":"2016","unstructured":"Kimball AB, Okun MM, Williams DA, Gottlieb AB, Papp KA, Zouboulis CC, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422\u201334.","journal-title":"N Engl J Med"},{"key":"880_CR17","doi-asserted-by":"crossref","unstructured":"Zouboulis CC, Okun MM, Prens EP, Gniadecki R, Foley PA, Lynde C, et al. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa\/acne inversa: 3-year results of a phase 3 open-label extension study. J Am Acad Dermatol. 2019;80(1):60-9. e2.","DOI":"10.1016\/j.jaad.2018.05.040"},{"issue":"5","key":"880_CR18","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1111\/jdv.16023","volume":"34","author":"H Van der Zee","year":"2020","unstructured":"Van der Zee H, Longcore M, Geng Z, Garg A. Weekly adalimumab treatment decreased disease flare in hidradenitis suppurativa over 36 weeks: integrated results from the phase 3 PIONEER trials. J Eur Acad Dermatol Venereol. 2020;34(5):1050\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"880_CR19","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.jaad.2018.05.015","volume":"79","author":"AB Kimball","year":"2018","unstructured":"Kimball AB, Sundaram M, Shields AL, Hudgens S, Okun M, Foley C, et al. Adalimumab alleviates skin pain in patients with moderate-to-severe hidradenitis suppurativa: secondary efficacy results from the PIONEER I and PIONEER II randomized controlled trials. J Am Acad Dermatol. 2018;79(6):1141\u20133.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"880_CR20","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/ced.14448","volume":"46","author":"J Frew","year":"2021","unstructured":"Frew J, Jiang C, Singh N, Grand D, Navrazhina K, Vaughan R, et al. Dermal tunnels influence time to clinical response and family history influences time to loss of clinical response in patients with hidradenitis suppurativa treated with adalimumab. Clin Experiment Dermatol. 2021;46(2):306\u201313.","journal-title":"Clin Experiment Dermatol."},{"issue":"11","key":"880_CR21","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1001\/jamasurg.2021.3655","volume":"156","author":"FG Bechara","year":"2021","unstructured":"Bechara FG, Podda M, Prens EP, Horv\u00e1th B, Giamarellos-Bourboulis EJ, Alavi A, et al. Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa: the SHARPS randomized clinical trial. JAMA Surg. 2021;156(11):1001\u20139.","journal-title":"JAMA Surg"},{"issue":"4","key":"880_CR22","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.jaad.2023.04.034","volume":"89","author":"P Aarts","year":"2023","unstructured":"Aarts P, van Huijstee JC, van der Zee HH, van Doorn MB, van Straalen KR, Prens EP. Adalimumab in conjunction with surgery compared with adalimumab monotherapy for hidradenitis suppurativa: a randomized controlled trial in a real-world setting. J Am Acad Dermatol. 2023;89(4):677\u201384.","journal-title":"J Am Acad Dermatol"},{"issue":"10378","key":"880_CR23","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","volume":"401","author":"AB Kimball","year":"2023","unstructured":"Kimball AB, Jemec GB, Alavi A, Reguiai Z, Gottlieb AB, Bechara FG, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): Week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet. 2023;401(10378):747\u201361.","journal-title":"Lancet"},{"key":"880_CR24","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.3389\/fimmu.2020.01894","volume":"11","author":"R Adams","year":"2020","unstructured":"Adams R, Maroof A, Baker T, Lawson AD, Oliver R, Paveley R, et al. Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F. Front Immunol. 2020;11:1894.","journal-title":"Front Immunol"},{"issue":"10443","key":"880_CR25","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","volume":"403","author":"AB Kimball","year":"2024","unstructured":"Kimball AB, Jemec GB, Sayed CJ, Kirby JS, Prens E, Ingram JR, et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. Lancet. 2024;403(10443):2504\u201319.","journal-title":"Lancet"},{"key":"880_CR26","unstructured":"UCB. Phase 3 data analysis presented at EADV 2023 showed bimekizumab achieved high thresholds of clinical response in hidradenitis suppurativa. Atlanta, GA: UCB; 2023. Available from: https:\/\/www.ucb-usa.com\/stories-media\/UCB-U-S-News\/detail\/article\/phase-3-data-analysis-presented-at-eadv-2023-showed-bimekizumab-achieved-high-thresholds-of-clinical-response-in-hidradenitis-suppurativa"},{"key":"880_CR27","doi-asserted-by":"crossref","unstructured":"Sayed C, Shi V, Hsiao J, Kokolakis G, Kirby B, Piguet V, et al. Bimekizumab efficacy by prior biologic treatment in patients with moderate to severe hidradenitis suppurativa: 48-week pooled data from the randomized, double-blind, placebo-controlled, multicenter BE HEARD I and II phase 3 trials. SKIN J Cutan Med. 2024;8(1):s349-s.","DOI":"10.25251\/skin.8.supp.349"},{"key":"880_CR28","doi-asserted-by":"crossref","unstructured":"Orenstein LA, Shi V, Lev-Tov H, Prens E, Podda M, Fujita H, et al. Bimekizumab impact on pain in moderate to severe hidradenitis suppurativa: week 16 results from BE HEARD I & II. SKIN J Cutan Med. 2024;8(1):s350-s.","DOI":"10.25251\/skin.8.supp.350"},{"key":"880_CR29","unstructured":"UCB. Latest analyses of bimekizumab phase 3 studies in moderate to severe hidradenitis suppurativa to be presented at EHSF 2024. Online: UCB; 2024. Available from: https:\/\/www.ucb.com\/stories-media\/Press-Releases\/article\/Latest-analyses-of-bimekizumab-phase-3-studies-in-moderate-to-severe-hidradenitis-suppurativa-to-be-presented-at-EHSF-2024"},{"issue":"11","key":"880_CR30","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1001\/jamadermatol.2021.2905","volume":"157","author":"S Glatt","year":"2021","unstructured":"Glatt S, Jemec GB, Forman S, Sayed C, Schmieder G, Weisman J, et al. Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind, placebo-controlled randomized clinical trial. JAMA Dermatol. 2021;157(11):1279\u201388.","journal-title":"JAMA Dermatol"},{"key":"880_CR31","unstructured":"Newswire P. ACELYRIN, INC. announces izokibep achieves HiSCR100 responses at 12 weeks in moderate-to-severe hidradenitis suppurativa. PR Newswire; 2023. Available from: https:\/\/www.prnewswire.com\/news-releases\/acelyrin-inc-announces-izokibep-achieves-hiscr100-responses-at-12-weeks-in-moderate-to-severe-hidradenitis-suppurativa-301775533.html"},{"key":"880_CR32","unstructured":"BioSpace. ACELYRIN, INC. announces top-line results from placebo-controlled clinical trial of izokibep for moderate-to-severe hidradenitis suppurativa. BioSpace; 2023. Available from: https:\/\/www.biospace.com\/article\/releases\/acelyrin-inc-announces-top-line-results-from-placebo-controlled-clinical-trial-of-izokibep-for-moderate-to-severe-hidradenitis-suppurativa\/"},{"issue":"5","key":"880_CR33","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1111\/bjd.20969","volume":"186","author":"A Alavi","year":"2022","unstructured":"Alavi A, Hamzavi I, Brown K, Santos LL, Zhu Z, Liu H, et al. Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies. Br J Dermatol. 2022;186(5):803\u201313.","journal-title":"Br J Dermatol"},{"key":"880_CR34","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00403-019-02012-w","volume":"312","author":"Y Hayran","year":"2020","unstructured":"Hayran Y, All\u0131 N, Y\u00fccel \u00c7, Akdo\u011fan N, Turhan T. Serum IL-36\u03b1, IL-36\u03b2, and IL-36\u03b3 levels in patients with hidradenitis suppurativa: Association with disease characteristics, smoking, obesity, and metabolic syndrome. Arch Dermatol Res. 2020;312:187\u201396.","journal-title":"Arch Dermatol Res"},{"issue":"3","key":"880_CR35","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/bjd.16019","volume":"178","author":"S Hessam","year":"2018","unstructured":"Hessam S, Sand M, Gambichler T, Skrygan M, R\u00fcddel I, Bechara F. Interleukin-36 in hidradenitis suppurativa: evidence for a distinctive proinflammatory role and a key factor in the development of an inflammatory loop. Br J Dermatol. 2018;178(3):761\u20137.","journal-title":"Br J Dermatol"},{"key":"880_CR36","doi-asserted-by":"crossref","unstructured":"Alavi A, Prens E, Kimball A, Krueger J, Mukhopadhyay S, Wang H, et al. Spesolimab for hidradenitis suppurativa: a proof-of-concept study. SKIN J Cutan Med. 2023;7(6):s286-s.","DOI":"10.25251\/skin.7.supp.286"},{"key":"880_CR37","doi-asserted-by":"crossref","unstructured":"Alavi A, Prens E, Kimball AB, Frew JW, Krueger JG, Mukhopadhyay S, et al. Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: A randomized, double-blind, placebo-controlled clinical trial. Br J Dermatol. 2024:ljae144.","DOI":"10.1093\/bjd\/ljae144"},{"key":"880_CR38","doi-asserted-by":"crossref","unstructured":"Kimball AB, Ackerman L, Schlosser BJ, Prajapati VH, Fretzin S, Takahashi H, et al. 43799 Efficacy and safety of upadacitinib in moderate-to-severe hidradenitis suppurativa: a phase 2, randomized, placebo-controlled study. J Am Acad Dermatol. 2023;89(3):AB42.","DOI":"10.1016\/j.jaad.2023.07.172"},{"key":"880_CR39","unstructured":"AbbVie. Lutikizumab showed positive results in a phase 2 trial of adults with moderate to severe hidradenitis suppurativa as program advances to phase 3. Abbvie News Center: Abbvie; 2024. Available from: https:\/\/news.abbvie.com\/2024-01-08-Lutikizumab-Showed-Positive-Results-in-a-Phase-2-Trial-of-Adults-with-Moderate-to-Severe-Hidradenitis-Suppurativa-as-Program-Advances-to-Phase-3"},{"key":"880_CR40","unstructured":"Immunotherapeutics M. MoonLake Immunotherapeutics achieves landmark milestone with positive hase 2 results for Nanobody\u00ae sonelokimab in hidradenitis suppurativa. MoonLake; 2023. Available from: https:\/\/ir.moonlaketx.com\/news-releases\/news-release-details\/moonlake-immunotherapeutics-achieves-landmark-milestone-positive"},{"key":"880_CR41","unstructured":"Immunotherapeutics M. MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody\u00ae sonelokimab as a highly promising and differentiated therapeutic solution for hidradenitis suppurativa. MoonLake; 2023. Available from: https:\/\/ir.moonlaketx.com\/news-releases\/news-release-details\/moonlake-immunotherapeutics-announces-full-dataset-its-24-week"},{"key":"880_CR42","unstructured":"Porter M, Ferreira-Cornwell MC, Wang M, Nawaz H, Gooderham M. Efficacy and safety of ruxolitinib cream in patients with hidradenitis suppurativa (Hurley stage I and II): Results from a randomized, double-blind, vehicle-controlled phase 2 study. 2024 Am Acad Dermatol Ann Meet. San Diego, CA; 2024. Available from:"},{"key":"880_CR43","doi-asserted-by":"crossref","unstructured":"Katsanos KH, Christodoulou DK, Tsianos EV. Axillary hidradenitis suppurativa successfully treated with infliximab in a Crohn's disease patient. Official J Am Coll Gastroenterol | ACG. 2002;97(8):2155-6.","DOI":"10.1111\/j.1572-0241.2002.05950.x"},{"issue":"3","key":"880_CR44","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.jaad.2019.05.022","volume":"81","author":"AN Oskardmay","year":"2019","unstructured":"Oskardmay AN, Miles JA, Sayed CJ. Determining the optimal dose of infliximab for treatment of hidradenitis suppurativa. J Am Acad Dermatol. 2019;81(3):702\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"880_CR45","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.jaad.2019.09.071","volume":"82","author":"MH Ghias","year":"2020","unstructured":"Ghias MH, Johnston AD, Kutner AJ, Micheletti RG, Hosgood HD, Cohen SR. High-dose, high-frequency infliximab: a novel treatment paradigm for hidradenitis suppurativa. J Am Acad Dermatol. 2020;82(5):1094\u2013101.","journal-title":"J Am Acad Dermatol"},{"key":"880_CR46","unstructured":"InflaRx. 07-2019-InflaRx reports additional analysis of the SHINE phase IIb results for IFX-1 in hidradenitis suppurativa. Germany; 2019. Available from: https:\/\/www.inflarx.de\/Home\/Investors\/Press-Releases\/07-2019-InflaRx-Reports-Additional-Analysis-of-the-SHINE-Phase-IIb-Results-for-IFX-1-in-Hidradenitis-Suppurativa-.html"},{"key":"880_CR47","unstructured":"InflaRx. 11-2019-InflaRx reports positive results from the open label extension part of the SHINE study for IFX-1 in hidradenitis suppurativa. 2019. Available from: https:\/\/www.inflarx.de\/Home\/Investors\/Press-Releases\/11-2019-InflaRx-Reports-Positive-Results-from-the-Open-Label-Extension-Part-of-the-SHINE-Study-for-IFX-1-in-Hidradenitis-Suppurativa.html"},{"issue":"38","key":"880_CR48","first-page":"920","volume":"2023","author":"C Frederiksen","year":"2023","unstructured":"Frederiksen C, Sedeh F, Taudorf E, Saunte D, Jemec G. Orismilast for the treatment of mild to severe hidradenitis suppurativa: week 16 data from OSIRIS, a phase 2a, open-label, single-centre, single-arm, dose-finding clinical trial. J Eur Acad Dermatol Venereol. 2023(38):920\u201330.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"880_CR49","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s13555-023-00913-3","volume":"13","author":"AB Kimball","year":"2023","unstructured":"Kimball AB, Prens EP, Passeron T, Maverakis E, Turchin I, Beeck S, et al. Efficacy and safety of risankizumab for the treatment of hidradenitis suppurativa: a phase 2, randomized, placebo-controlled trial. Dermatol Ther. 2023;13(5):1099\u2013111.","journal-title":"Dermatol Ther"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-024-00880-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-024-00880-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-024-00880-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T07:36:42Z","timestamp":1724830602000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-024-00880-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,26]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["880"],"URL":"https:\/\/doi.org\/10.1007\/s40257-024-00880-1","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,26]]},"assertion":[{"value":"8 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr. Alexa B. Kimball\u2019s institution received grants from Abbvie, Admirx, Anapyts Bio, Aristea, Bristol Myers Squibb, Eli Lilly, Incyte, Janssen, Moonlake, Novartis, Pfizer, Prometheus, UCB, and Sonoma Bio. Drs. Gao and Otto received fellowship funding from Janssen and Abbvie. Dr. Kimball received consulting fees from Abbvie, Alumis, Bayer, Boehringer Ingelheim, Eli Lilly, Evoimmune, Janssen, Moonlake, Novartis, Pfizer, Priovant, Sonoma Bio, Sanofi, UCB, and Target RWE; and she serves on the board of directors of Almirall. Dr. Martina Porter is a consultant and\/or investigator for Abbvie, Bristol Meyers Squibb, Janssen, Eli Lilly, Moonlake, Novartis, Pfizer, SonomaBio, Trifecta Clinical (on behalf of Acelyrin), UCB, Aristea, Regeneron, Innovoderm, Bayer, Alumis, Sanofi, and Incyte.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent to participate\/publish"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Material preparation was performed by Julia Gao, MD. The first draft of the manuscript was written by Julia Gao, MD, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Exempt from review.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"IRB approval status"}}]}}